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ABSTRACT Studies by various investigators have indi-
cated that elevated levels of plasma homocyst(e)ine are
strongly associated with the occurrence of occlusive vascular
diseases. With the eventual aim of determining whether or not
elevated plasma homocyst(e)ine concentrations are directly
causative of cardiovascular diseases, we have generated mice
that are moderately and severely homocyst(e)inemic. Homol-
ogous recombination in mouse embryonic stem cells was used
to inactivate the cystathionine 13-synthase [L-serine hydro-
lyase (adding homocysteine), EC 4.2.1.22] gene. Homozygous
mutants completely lacking cystathionine 13-synthase were
born at the expected frequency from matings ofheterozygotes,
but they suffered from severe growth retardation and a ma-
jority of them died within 5 weeks after birth. Histological
examination showed that the hepatocytes of homozygotes were
enlarged, multinucleated, and filled with microvesicular lipid
droplets. Plasma homocyst(e)ine levels of the homozygotes
were "40 times normal. These mice, therefore, represent a
model for severe homocyst(e)inemia resulting from the com-
plete lack of cystathionine 18-synthase. Heterozygous mutants
have 509o reduction in cystathionine 8-synthase mRNA and
enzyme activity in the liver and have twice normal plasma
homocyst(e)ine levels. Thus, the heterozygous mutants are
promising for studying the in vivo role of elevated levels of
homocyst(e)ine in the etiology of cardiovascular diseases.
Homocysteine is an intermediate amino acid in methionine
metabolism and is either converted to cysteine by transsulfu-
ration or methylated to form methionine. A decreased rate of
metabolism through either of these pathways can lead to
homocyst(e)inemia and homocystinuria.
The most common type of inherited homocystinuria is
caused by a deficiency in cystathionine ,B-synthase [CBS; L-
serine hydro-lyase (adding homocysteine), EC 4.2.1.22]. CBS
is the rate-limiting enzyme of the transsulfuration pathway that
condenses homocysteine and serine into cystathionine. One in
300,000 newborns is homozygous for a deficiency in CBS (1).
The major clinical manifestations of homozygotes include
mental retardation, ectopia lentis, osteoporosis, skeletal ab-
normalities, and fatty liver. Premature arteriosclerosis and
thromboembolism are characteristics of patients with severe
homocystinuria, and thromboembolic complications are the
most frequent cause of death in these patients (1, 2).
Elevated levels of plasma homocyst(e)ine§ have attracted
much attention in recent years as a potential risk factor for the
development of premature occlusive atherosclerosis in hu-
mans. Several studies have found that patients with premature
coronary artery disease have significantly higher levels of
homocyst(e)ine than control subjects (3-8). Although the role
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of elevated homocyst(e)ine in the formation of thrombi or in
the acceleration of atherogenesis is not well understood, var-
ious experiments suggest that homocysteine is a mediator of
disease. For example, homocysteine damages cultured human
venous and arterial endothelial cells (9, 10). Furthermore,
DeGroot et al. (11) showed that cells grown from obligate
heterozygotes for CBS deficiency were much more sensitive to
methionine-mediated injury than were control cells. Other in
vitro studies have demonstrated that homocysteine enhances
autooxidation of low density lipoproteins (12), enhances bio-
synthesis of thromboxane (13), inhibits cell-surface thrombo-
modulin expression (14), promotes vascular smooth muscle
cell growth (15), and enhances binding of lipoprotein(a) to
fibrin (16). In vivo, long-term infusion of homocystine in
baboons leads to endothelial desquamation, to an increase in
platelet consumption, and to arterial lesions (17). However,
there are also conflicting data indicating that an increased
incidence of vascular diseases was not found in individuals
heterozygous for homocystinuria (18, 19).
Determining whether elevated plasma homocyst(e)ine lev-
els are causative of cardiovascular disease or are a conse-
quence of the disease has been difficult because of the lack of
an experimental animal model system. We here describe the
generation of mice with CBS deficiency by gene targeting in
embryonic stem (ES) cells. The resulting homozygous mutant
mice having severe homocyst(e)inemia and the heterozygous
mutants having moderate homocyst(e)inemia are both useful
as models for pathophysiological studies of human diseases, as
well as for evaluating the correlation between elevated plasma
homocyst(e)ine levels and cardiovascular diseases.
MATERIALS AND METHODS
Cloning of the Mouse Cbs Gene and Construction of the
Targeting Plasmid. A 142-bp DNA fragment containing exon
3 of the rat Cbs gene was amplified from rat genomic DNA
with primers designed from published sequences (20). This
fragment was used as a probe to screen a A phage library made
from strain 129 mouse genomic DNA. A clone containing a
part of the mouse Cbs gene was isolated and its restriction map
was determined. A partial nucleotide sequence of the clone
was determined in order to localize exons of the mouse Cbs
gene that are homologous to exons 3, 4, and 8 of the rat and
human Cbs genes (20, 21). In constructing the targeting plas-
mid (Fig. 1), a 1.4-kb fragment containing exon 2 and a 7-kb
fragment containing exons 5-10 were used as the two arms of
Abbreviations: CBS, cystathionine f3-synthase; ES cells, embryonic
stem cells.
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FIG. 1. Targeted disruption of the mouse Cbs gene. (A) Endoge-
nous Cbs gene. Exons 2-10 are shown by boxes and numbered. Exons
2, 3, 4, 8, and 10 (solid boxes) were positioned by hybridization or by
nucleotide sequence determination. The other exons (stippled boxes)
are diagrammed by analogy to the rat gene (20). (B) Targeting con-
struct. Neo gene (NEO) replacing exons 3 and 4 is in the same
orientation as the Cbs gene. Thymidine kinase (TK) gene is oppositely
oriented. Broken line indicates vector sequence. A 1.4-kb HindIII
fragment and a 7-kb Kpn I/HindlIl fragment were used as the two
arms of homology. The HindIII site of the 7-kb fragment was from the
phage vector cloning site. (C) Correctly targeted locus depicted after
a homologous crossover. Arrowheads indicate positions of the two
primers used for PCR analysis. A probe for Southern blot analysis and
sizes of BamHI fragments detected by it are indicated. B, BamHI; K,
Kpn I; H, HindIII; N, Not I.
homology flanking the pMClneopolA sequence (Stratagene).
The herpes simplex thymidine kinase gene was positioned
downstream of the longer arm of homology (22).
Gene Targeting and Production of Mice from Modified ES
Cells. BK4 cells, a subclone of E14TG2a (23) derived from
strain 129/Ola mice, were cultured on feeder cells as described
(24). The construct was linearized with Not I and introduced
into ES cells by electroporation. Three experiments were
carried out, each using 2 x 107 cells and 10 ,ug of targeting
plasmid DNA. Colonies doubly resistant to G418 (200 ,ug/ml)
and ganciclovir (2 ,uM; a gift from Syntex, Palo Alto, CA) were
screened for homologous recombination by PCR (25). Primers
5'-GCCTCTGTCTGCTAACCTA-3' and 5'-GAGGTCGAC-
GGTATCGATA-3', corresponding, respectively, to a se-
quence from the Cbs gene outside the targeting construct and
to the linker sequence at the 5' end of the Neo gene, gave a
1.5-kb diagnostic PCR product. Southern blot analysis was
used to confirm the targeting, using as a probe the 1.4-kb
HindIII fragment shown in Fig. 1. Cells with a disrupted Cbs
gene were injected into blastocysts to obtain chimeras as
described (26). Animals classified as chimeric by coat color
were mated with strain C57BL/6J mice, and F1 animals het-
erozygous for the disrupted Cbs gene were obtained. Mice
were handled following the National Institutes of Health
guidelines for the care and use of experimental animals and
were fed autoclaved chow (RMH 3500; Agway, Syracuse, NY).
Plasma Homocyst(e)ine Measurements. Blood samples ob-
tained from retroorbital bleeding under anesthesia with 2,2,2-
tribromoethanol were collected into tubes containing EDTA,
aprotinin, and gentamicin as described (27). Plasma was col-
lected by centrifugation and stored at -70°C. Plasma homo-
cyst(e)ine levels were determined as described (4) with 50 ,ul
of plasma.
Student's t test of unpaired observations was used to deter-
mine statistical significance.
Northern Blotting ofmRNA and Enzyme Assay. Livers were
isolated from five 21-day-old mice of each genotype. Equal
weights of tissues from five animals of each genotype were
pooled, and total RNA was extracted according to the method
of Chomczynski and Sacchi (28) using RNazol (Tel-Test,
Friendswood, TX). Poly(A)+ RNA was prepared as described
by Kingston (29). Northern blots were prepared by standard
methods (30) and hybridized to a 1.4-kb HindIII fragment
containing exon 2 or a 3-kb fragment containing exons 8 and
9 of the mouse Cbs gene or to a PCR fragment containing exon
3 of the rat Cbs gene. A cDNA clone for human glyceralde-
hyde-3-phosphate dehydrogenase (Clontech) was used as a
probe to evaluate the amount ofmRNA loaded. mRNA levels
were estimated by densitometric analysis of autoradiograms
after serial exposures.
Equal weights of liver tissues from five animals of each
genotype were combined and homogenized in 3 vol of 1.15%
KCI. After centrifugation at 10,000 x g for 15 min, CBS activity
was measured in the supernatant by the method of Kashi-
wamata and Greenberg (31). Protein concentrations were
measured by a dye binding procedure (Bio-Rad).
Histological Analysis. Mice were sacrificed by an overdose
of 2,2,2-tribromoethanol, and the heart, eye, lung, liver, kid-
ney, spleen, and knee joint were excised and fixed in 4%
paraformaldehyde/0.1 M sodium phosphate buffer (pH 8).
The bone was decalcified by immersion in 0.5 M EDTA (pH
8) for 1 week. Paraffin sections of the tissues were stained with
hematoxylin and eosin. Frozen sections of the liver were
stained with Sudan IVB and hematoxylin.
RESULTS
Targeted Disruption of the Mouse Cbs Gene. The targeting
plasmid is illustrated in Fig. 1. Swaroop et al. (20) have shown
that the rat Cbs gene produces at least four mRNAs resulting
from alternative splicing of transcripts; all the functionally
active mRNAs contain exon 3, where Lys-116 resides. The
authors showed that the CBS protein shares sequence simi-
larity with other pyridoxal 5'-phosphate-dependent enzymes,
including those from lower organisms. Lys-116 is most likely
the pyridoxal 5'-phosphate binding residue of CBS because it
aligns with the established pyridoxyllysine in other enzymes.
We therefore made a targeting construct so that exons 3 and
4 of the mouse Cbs gene will be replaced by the bacterial Neo
gene after the planned targeting (Fig. 1C).
A total of 360 colonies doubly resistant to G418 and Gan-
ciclovir were analyzed by PCR, and 13 candidate targeted cell
lines were identified. Modification of the Cbs locus was con-
firmed by Southern blot analysis ofDNA from these cells after
digestion with various restriction enzymes including BamHI,
Kpn I, and Cla I (data not shown). Four cell lines were injected
into recipient blastocysts, and 16 chimeras were generated.
Three of these chimeras transmitted the modified Cbs gene to
the next generation.
Mice Deficient for CBS. The resulting heterozygotes grew
normally and were outwardly healthy. But when the heterozy-
gotes were bred to produce homozygotes for the disrupted
gene, we found that the homozygotes did not thrive. At wean-
ing (postnatal day 21), the ratio of wild-type to heterozygous
mice was very close to the expected ratio of 1:2 (80:151).
However, the number of homozygotes was significantly lower
than expected (42 observed vs. 77 expected; P < 0.001). The
number of surviving homozygotes decreased to 18 at 4 weeks
and to 15 at 8 weeks. Fig. 2 presents the number of homozy-
gotes surviving at weekly intervals after birth as percentage of
the expected number. As indicated above, the homozygotes
were born at close to the expected percentage, and there was
no significant reduction in their number until postnatal day 14.
This result suggests that inactivation of the Cbs gene does not
affect embryonic survival but that it results in a high incidence
of death during the 3rd and 4th postnatal weeks.
We followed the growth of pups by measuring their body
weights (Table 1). There was no significant difference in body
weights among mice of the three genotypes at postnatal days
1 and 7. However, homozygous mutants failed to gain weight
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FIG. 2. Number of homozygous mice expressed as a percentage of
that expected from numbers of wild-type and heterozygous litter-
mates. On days 1, 7, and 14, pups (n = 55, 42, and 68, respectively) were
sacrificed and genotyped by Southern blot analysis (open circles). All
remaining animals were genotyped at day 21, and survival of the 42
homozygotes was followed (solid circles).
thereafter, and their body weights at day 14 were "80% of the
weights of wild-type and heterozygous mice (P < 0.02). From
day 14 to day 21, homozygotes showed little weight gain, so that
there was an even larger difference in body weight between the
homozygous mutants and wild-type animals at day 21 (P <
0.001). The homozygotes that died at the early postnatal stages
were those with lower body weight. They also had character-
istics suggestive of growth retardation, such as delayed eye
opening and facies typical of very young animals. In addition,
their tails and extremities were smaller in diameter relative to
their length when compared to wild-type mice.
To date, 12 homozygous mice (4 males and 8 females) have
survived >2 months. These mice, in contrast to those that died
early, have nearly normal stature at weaning. They maintain a
relatively normal body size thereafter until just before death.
A strong correlation is, therefore, observed between the se-
verity in growth retardation and the failure to survive in the
mice lacking CBS. Two surviving male F2 homozygotes both
reproduced when mated to F2 heterozygous females. The
survival rate of their homozygous offspring was similar to that
of the homozygous offspring from matings between the F1
heterozygotes. None of four homozygous females so far tested
has reproduced.
A single transcript was detected by Northern blot analysis of
liver mRNA from wild-type and heterozygous animals with a
probe made from a PCR fragment containing exon 3 of the rat
Cbs gene (Fig. 3). The same transcript was also detected by
probes containing exon 2 or exons 8 and 9 of the mouse Cbs
gene. None of these probes, however, showed specific hybrid-
ization to mRNA from the homozygotes, indicating that the
homozygotes do'not make any detectable CBS transcripts. The
amount of mRNA in the liver of heterozygotes was estimated
to be -45% that of wild-type animals by densitometric anal-
ysis. Enzyme activity was not detectable in liver homogenates
from homozygous mice, while enzyme activity in the liver from
heterozygotes was 42% that in the liver of wild-type mice (0.42
vs. 1.00 ,umol/hr of cystathionine production per mg of protein
of liver extract).
Table 1. Growth of pups from heterozygous F1 matings
Postpartum Body weight, g
age, days Wild type Heterozygotes Homozygotes
1 1.4 ± 0.3 (13) 1.5 ± 0.3 (25) 1.5 ± 0.2 (15)
7 4.3 ± 0.9 (15) 4.0 ± 1.0 (22) 4.2 ± 1.0 (12)
14 7.5 ± 1.2 (20) 7.4 ± 1.9 (31) 6.0 ± 1.3 (17)*
21 9.8 ± 2.3 (29) 9.2 ± 2.4 (56) 6.4 ± 1.3 (16)t
Values are expressed as means ± SD. Mice from 7-14 litters at each
postpartum day were weighed, sexed, and genotyped. Numbers of mice
are given in parentheses. There were no statistical differences between
body weights of males and females.
*P < 0.02 against wild-type and heterozygous mice.




FIG. 3. Northern blot analysis of liver mRNA. Poly(A) RNA (2 ,ug)
isolated from livers of wild-type mice (+/+), homozygous mutants
(-/-), and heterozygous mutants (+/-) were electrophoresed, blot-
ted, and hybridized to a DNA fragment containing exon 3 of the rat
Cbs gene. Amounts of RNA loaded are depicted by hybridization to
a cDNA probe for human glyceraldehyde-3-phosphate dehydrogenase
(G3PD).
Plasma Homocyst(e)ine Concentrations in CBS-Deficient
Mice. The plasma homocyst(e)ine levels in 21-day-old F2 ho-
mozygotes were -40 times higher than those of age-matched
normal littermates (Fig. 4A). Heterozygotes have about twice
the normal homocyst(e)ine levels. We also measured the
plasma homocyst(e)ine levels in wild-type and heterozygous F1
male mice at 3, 12, 22, and 44 weeks after birth (Fig. 4B).
Plasma concentrations decreased with age, reaching levels of
3 nmol/ml and 7 nmol/ml, respectively, by 22 weeks of age; the
1:2 ratio between wild type and heterozygotes was observed at
all time points. As the genetic background of all F1 animals is
identical, we conclude that this 1:2 ratio is directly caused by
the mutation.
Histological Observations of Homozygous CBS Mutants.
Most homozygotes at weaning were runted and their eyes were
smaller than normal and not completely open. The 21-day-old
homozygous mutants, which were doing well and were vigor-
ous at this time, were sacrificed for histological examination.
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FIG. 4. Plasma homocyst(e)ine levels in CBS-deficient mice. (A)
Mean plasma homocyst(e)ine levels in 21-day-old F2 mice. Both fe-
males and males are represented. Values were 6.1 ± 0.8 nmol/ml in
wild-type (+/+; n = 5), 13.5 + 3.2 nmol/ml in heterozygous (+/-;
n = 7), and 203.6 ± 65.3 nmol/ml in homozygous (-/-; n = 6) mice.
*, P < 0.001 against wild type. (B) Decrease in plasma homocyst(e)ine
levels with age. Plasma homocyst(e)ine levels of wild-type and het-
erozygous F1 male animals were measured at 12, 22, and 44 weeks of
age. Levels at the 3-week time point were obtained from different F1
males. At all times, levels in heterozygotes are statistically different
from those in wild type (n = 5; P < 0.001).
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FIG. 5. Hepatic morphology of 21-day-old normal, heterozygous, and homozygous CBS-deficient mice. Normal hepatic morphology consists
of uniform hepatocytes with bland nuclei that contain small nucleoli (A). In heterozygous mice (B), the hepatocytes have anisonucleosis and fairly
prominent nucleoli and appear to be slightly larger. Homozygous animals (C) have enlarged pleomorphic hepatocytes with large, prominent nucleoli.
The hepatocytes are frequently binucleated or multinucleated, and their cytoplasm often contains multivesicular cytoplasmic lipid droplets. (x 130.)
ences except that the color of the livers was light tan in contrast
to the reddish-brown color of the livers of heterozygotes and
wild-type mice.
The morphology of hepatocytes from the 21-day-old ho-
mozygous mice was abnormal, as judged by light microscopic
observation (Fig. 5). The hepatocytes were enlarged and had
an approximately twice normal mean diameter (29.2 ± 11.0 vs.
14.3 ± 2.5 ,um). Their nuclei were also enlarged. Multinucle-
ated and binucleated hepatocytes were evident. In some hepa-
tocytes from the homozygous mutants, the cytoplasm was
filled with microvesicular lipid droplets. The hepatocytes of
the heterozygotes and wild-type mice showed no microvesicu-
lar fat droplets. Extramedullary hematopoiesis was prominent
in the liver of homozygotes, in contrast to its virtual absence
in the livers of heterozygotes and wild-type mice. The livers of
1- and 7-day-old homozygotes were not distinguishable from
the livers of their wild-type littermates, but the hepatocytes in
14-day-old homozygotes were abnormal (data not shown).
No pathological changes were notable in the eyes, knee
joints, kidneys, lungs, and hearts ofhomozygous mice at day 21,
except that they appeared immature when compared to their
21-day-old wild-type and heterozygous littermates. Hemosi-
derin deposition was observed in the spleen of one of four
21-day-old homozygous mutant mice. Thrombi were absent in
vascular segments and other tissues from all the mice.
Postmortem evaluations of two older homozygotes, a 3-mo-
old female and a 6-mo-old female, showed hepatomegaly and
mild autolytic changes. Their livers had histologic changes
similar to the younger homozygous mice described above. The
immediate causes of death of these animals were not clear.
DISCUSSION
Increased levels of plasma homocyst(e)ine are observed as a
consequence of several different inborn errors of metabolism,
including deficiency in CBS, abnormalities in 5-methyltetra-
hydrofolate reductase, and several conditions that lead to
vitamin B12, vitamin B6, or folate deficiencies (1). The muta-
tion we have introduced into mice disrupts the Cbs gene and
completely eliminates expression of the gene, as determined by
the absence of enzyme activity and of mRNA in the livers of
homozygotes. Plasma homocyst(e)ine levels in the homozy-
gotes were 40 times normal. Heterozygous mutants had half
normal levels of enzyme activity in the liver and twice normal
levels of plasma homocyst(e)ine.
Levels of plasma homocyst(e)ine and tissue CBS activities
are heterogenous among different human patients with CBS
deficiencies. The severity of the clinical symptoms also varies
significantly. Some patients respond well to the administration
of pyridoxine, while others do not (1). At least a part of this
heterogeneity is the result of different molecular lesions. For
example, individuals homozygous for a G307S replacement are
nonresponsive to pyridoxine treatment, while individuals ho-
mozygous for an I278T replacement are responsive to pyri-
doxine (32).
The homozygous mutant mice lacking the CBS enzyme
represent the extreme end of the spectrum of human cases.
They are born normal but suffer from severe growth retarda-
tion; the majority die before 4 weeks of age. The livers of
21-day-old homozygotes are abnormal, characterized by en-
larged and multinucleated hepatocytes with lipid droplets and
by extramedullary hematopoiesis. Although similar liver hy-
pertrophy and fatty droplet inclusions unaccompanied by fi-
brosis have been found by liver biopsy or at autopsy in virtually
all human patients with homocystinuria (1), they are not the
major cause of morbidity. Untreated homozygous mice lacking
CBS have more severe liver damage than human patients, and
this liver abnormality in mice is likely to contribute to their
growth retardation and early death. Growth retardation has
been observed in rats fed excessive methionine or homocystine
(33), but it is not a characteristic of the human patients.
Northern blot analysis of mRNA isolated from the livers of
homozygous mutants showed no detectable transcripts for the
Cbs gene (Fig: 3).
A consistent finding in human CBS deficiency is dislocation
of the lens. We noted above that most of the homozygous
mutant mice have delayed and narrow eye openings, but no
histological abnormalities were obvious in their eyes. Whether
other pathological conditions found in human CBS-deficient
patients, such as osteoporosis and vascular occlusions, will
appear after longer survival of the homozygotes remains to be
determined. Restriction of dietary methionine, administration
of betaine, or transfer into the mice of a temporarily expressed
CBS gene may allow the homozygotes to survive longer. This
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in turn would allow the occurrence of the more progressive
changes described in humans to be evaluated.
We found that a small fraction of homozygous F2 animals
mature to adulthood. Since these mice are F2 animals, derived
from matings between heterozygous F1 (C57BL/6J and 129)
animals, their genetic compositions differ. It is, therefore,
conceivable that there exist other genetic factors that amelio-
rate the deleterious effect of CBS deficiency. However, against
this possibility is our observation that pups resulting from
breeding surviving homozygous males to heterozygous females
died in roughly the same proportion as in the previous gen-
eration. Nongenetic factors, such as birth order, litter size, and
body weight at birth may influence the ability to survive.
When considering the elevated plasma levels of homocys-
t(e)ine as a risk factor for heart diseases, the mean homocys-
t(e)ine levels in patients with occlusive vascular diseases are
1.3-1.5 times those of controls (8). In this sense, we are
encouraged to find that the elevations in heterozygous mice
are to levels comparable to those observed in humans. It is,
therefore, reasonable to expect that studies of heterozygous
CBS-deficient mice will generate important insights into the
overall process of atherogenesis. For example, the mutant Cbs
gene can be introduced into mice lacking apolipoprotein E,
which develop atherosclerosis spontaneously (27, 34), to assess
the effects of moderate homocyst(e)inemia combined with
elevated levels of chylomicron remnants and low density li-
poprotein remnants.
In conclusion, we have generated mice carrying the dis-
rupted Cbs gene. The homozygous CBS null mice with severe
homocyst(e)inemia should be useful for increasing our under-
standing of the pathophysiology of CBS deficiency, as well as
for developing new means of treatment. The apparently
healthy heterozygotes with twice the normal plasma homo-
cyst(e)ine levels are promising for studying the in vivo role of
moderately elevated homocyst(e)ine levels on the etiology of
cardiovascular diseases.
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